The Technical Analyst
Astellas Pharma Inc. [ALPMY]
Exchange: OTC Sector: Healthcare Industry: Drug Manufacturers—General
Astellas Pharma Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.70% $10.04
America/New_York / 3 mai 2024 @ 15:59
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 18 003 mill |
| EPS: | 0.0200 |
| P/E: | 502.00 |
| Earnings Date: | Jul 29, 2024 |
| SharesOutstanding: | 1 793.10 mill |
| Avg Daily Volume: | 0.328 mill |
| RATING 2024-05-03 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Sell | |
| Return On Asset: | Sell | |
| DE: | Buy | |
| P/E: | Strong Sell | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | 1/24 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 17.28x |
| Company: PE 502.00 | sector: PE 29.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 12.05x |
| Company: PE 502.00 | industry: PE 41.65 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$26.37 (162.63%) $16.33 |
| Date: 2024-05-05 |
| Expected Trading Range (DAY) |
|---|
|
$ 9.69 - 10.39 ( +/- 3.45%) |
| ATR Model: 14 days |
Forecast:
16:00 - $10.04
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $10.04
Forecast 2: 16:00 - $10.04
Forecast 3: 16:00 - $10.04
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $10.04 (0.70% ) |
| Volume | 0.258 mill |
| Avg. Vol. | 0.328 mill |
| % of Avg. Vol | 78.65 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For ALPMY
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
ALPMY
Astellas Pharma Inc. engages in the manufacture, marketing, import, and export of pharmaceuticals worldwide. It provides XTANDI, an androgen receptor signaling inhibitor for prostate cancer; XOSPATA, a FLT3 inhibitor for adult patients with relapsed or refractory acute myeloid leukemia with a FLT3 mutation-positive; PADCEV, a treatment solution for adult patients with locally advanced or metastatic urothelial cancer; Betanis/Myrbetriq/BETMIGA, a beta-3 adrenergic receptor agonist for the treatment of urgency, urinary frequency, and urge urinary incontinence; Evrenzo, an oral treatment for anemia associated with chronic kidney disease; and Prograf and Advagraf/Graceptor/ASTAGRAF, which are immunosuppressants used to suppress organ rejection following a transplant. The company also offers mirabegron for the treatment of neurogenic detrusor overactivity in pediatric patients; Vesicare for OAB treatment; Eligard to treat prostate cancer; Harnal/Omnic for benign prostatic hyperplasia treatment; and Funguard/MYCAMINE, an antifungal agent. The company has a clinical trial collaboration with Merck & Co., Inc.; CytomX Therapeutics, Inc.; and an agreement with BANDAI NAMCO Entertainment Inc. for the development of smartphone exercise support application. It also has strategic research alliance with Harvard University for the research and development of therapeutics and technologies of mutual interest; research collaboration with Actinium Pharmaceuticals, Inc. to develop targeted radiotherapies using its Antibody Warhead Enabling technology platform, as well as agreement with Zenith Epigenetics Ltd. to evaluate ZEN-3694; and collaboration agreement with Cytokinetics, Incorporated. The company has a strategic collaboration and license agreement with Minovia Therapeutics Ltd. for the research, development, and commercialization of cell therapy programs for diseases caused by mitochondrial dysfunction. Astellas Pharma Inc. was founded in 1923 and is headquartered in Tokyo, Japan.
Latest Press Releases
2024-05-01 21:30:00 - Press Release
Astellas And Poseida Therapeutics Enter Into Research Collaboration And License Agreement To Develop Novel Allogeneic Cell Therapies In Oncology
- leverages poseida's proprietary allogeneic car-t platform to develop innovative convertiblecar® programs targeting solid tumors - tokyo and san diego , may 1, 2024 /prnewswire/ -- astellas pharma inc. (tse: 4503, president and ceo: naoki okamura, "astellas") and poseida therapeutics, inc. (nasdaq: pstx, president and ceo: kristin yarema, "poseida") today announced that xyphos biosciences, inc., (a wholly owned subsidiary of astellas, "xyphos") and poseida have entered into a research collaboration and license agreement to develop novel convertiblecar® programs by combining the innovative cell therapy platforms from each of the companies. poseida is advancing differentiated cell and gene therapies with the capacity to cure certain cancers and rare diseases.
2024-04-23 19:30:00 - Press Release
Astellas' Xtandi™ (enzalutamide) Granted European Commission Approval For Use In Additional Recurrent Early Prostate Cancer Treatment Setting
Xtandi is now the first and only novel hormone therapy available for the treatment of high-risk biochemical recurrent non-metastatic hormone-sensitive prostate cancer in the european union (eu) xtandi can be given alone or in combination with androgen deprivation therapy approval is based on results from the positive phase 3 embark study which showed xtandi alone or in combination with leuprolide reduced the risk of metastasis or death tokyo , april 23, 2024 /prnewswire/ -- astellas pharma inc. (tse: 4503, president and ceo: naoki okamura, "astellas") today announced the european commission (ec) has approved a label extension for xtandi™ (enzalutamide) as monotherapy or in combination with androgen deprivation therapy (adt) for the treatment of adult men with high-risk biochemical recurrent (bcr) non-metastatic hormone-sensitive prostate cancer (nmhspc) who are unsuitable for salvage-radiotherapy...
2024-03-28 11:00:00 - Press Release
China's National Medical Products Administration Accepts Astellas And Pfizer's Supplemental Biologics License Application For Enfortumab Vedotin With Keytruda® (pembrolizumab) For First-line Treatment Of Advanced Bladder Cancer
- pivotal trial found the enfortumab vedotin plus pembrolizumab combination significantly extended overall and progression-free survival vs platinum-containing chemotherapy- - if approved, enfortumab vedotin with keytruda would be the first combination in china to offer an alternative to chemotherapy, the current standard of care in first-line locally advanced or metastatic urothelial cancer- tokyo , march 28, 2024 /prnewswire/ -- astellas pharma inc. (tse:4503, president and ceo: naoki okamura, "astellas") today announced that on march 27, 2024 the center for drug evaluation (cde) of the china national medical products administration (nmpa) has accepted the supplemental biologics license application (sbla) for enfortumab vedotin with keytruda® (pembrolizumab) as a combination therapy for the first-line treatment of adult patients with previously untreated locally advanced or metastatic urothelial cancer (la/muc)...
2024-03-26 08:30:00 - Press Release
Astellas Receives Permanent J-code For Izervay™ (avacincaptad Pegol Intravitreal Solution) For Geographic Atrophy
Permanent j-code j2782 effective april 1, 2024 northbrook, ill. , march 26, 2024 /prnewswire/ -- iveric bio, an astellas company (tse: 4503, president and ceo: naoki okamura, "astellas"), today announced the u.s. centers for medicare and medicaid services (cms) has assigned a unique, permanent healthcare common procedure coding system (hcps) j-code for izervay™ (avacincaptad pegol intravitreal solution) for the treatment of geographic atrophy (ga) secondary to age-related macular degeneration (amd).
2024-03-26 08:00:00 - Press Release
Astellas' Vyloy™ (zolbetuximab) Approved In Japan For Treatment Of Gastric Cancer
Vyloy approved in combination with chemotherapy for patients with human epidermal growth factor receptor 2 (her2)-negative, cldn18.2 positive, unresectable, advanced or recurrent gastric cancer mhlw approval makes vyloy the first and only cldn18.2-targeted therapy approved in the world tokyo , march 26, 2024 /prnewswire/ -- astellas pharma inc. (tse: 4503, president and ceo: naoki okamura, "astellas") today announced that on march 26, 2024, japan's ministry of health, labour and welfare (mhlw) approved vyloy™ (zolbetuximab), an anti-claudin 18.2 (cldn18.2) monoclonal antibody for patients with cldn18.2 positive, unresectable, advanced or recurrent gastric cancer. vyloy is the first and only cldn18...
Latest News
2024-01-08 19:01:48 - Reuters
US FDA declines to approve Astellas' gastric cancer drug
Japan's Astellas Pharma said on Monday the U.S. Food and Drug Administration (FDA) has declined to approve its experimental drug to treat a type of gastric cancer, citing issues related to a third-party manufacturer.
2023-12-18 07:39:57 - Proactive Investors
Astellas gets green light from European Commission for menopause drug
The European Commission has approved Astellas Pharma's fezolinetant, a non-hormonal treatment for managing moderate-to-severe vasomotor symptoms (VMS) like hot flashes and night sweats in menopausal women. This approval addresses a large unmet need, as up to 97% of women aged 40 to 64 in Europe experience these symptoms.
2023-11-02 00:06:09 - Seeking Alpha
Astellas Pharma Inc. (ALPMF) Q2 2023 Earnings Call Transcript
Astellas Pharma Inc. (OTCPK:ALPMF) Q2 2023 Earnings Conference Call November 1, 2023 3:00 AM ET Company Participants Hiromitsu Ikeda - Corporate Head, Advocacy & Relations Atsushi Kitamura - Chief Financial Officer Naoki Okamura - Representative Director, President & Chief Executive Officer Yoshitsugu Shitaka - Chief Scientific Officer Tadaaki Taniguchi - Chief Medical Officer Claus Zieler - Chief Commercial Officer Conference Call Participants Hidemaru Yamaguchi - Citigroup Securities Kazuaki Hashiguchi - Daiwa Securities Shinichiro Muraoka - Morgan Stanley MUFJ Securities Seiji Wakao - JPMorgan Securities Akinori Ueda - Goldman Sachs Securities Shinya Tsuzuki - Mizuho Securities Hiromitsu Ikeda Thank you very much for joining Astellas Pharma Inc...
2023-10-02 09:01:06 - Zacks Investment Research
New Strong Sell Stocks for October 2nd
ALPMY, BTDPY and ALRS have been added to the Zacks Rank #5 (Strong Sell) List on October 2, 2023.
2023-09-26 07:31:27 - Zacks Investment Research
New Strong Sell Stocks for September 26th
ALPMY, ASH and DHC have been added to the Zacks Rank #5 (Strong Sell) List on September 26, 2023.
2023-09-18 08:17:09 - Zacks Investment Research
New Strong Sell Stocks for September18th
ALPMY, CBRE and FMAO have been added to the Zacks Rank #5 (Strong Sell) List on September 18, 2023.
2023-09-06 14:19:21 - Reuters
Astellas withdraws lawsuit challenging Medicare drug price negotiation plans
Japan-based Astellas Pharma on Wednesday withdrew a lawsuit filed against the U.S. government, days after its prostate cancer drug was spared from the first list of drugs that will be subject to Medicare price negotiations.
2023-09-01 07:01:24 - MarketBeat
How Much Pain Will Lower Medicare Prices Cause for Pharma Stocks?
Major pharmaceutical companies including Johnson & Johnson NYSE: JNJ, Novartis AG NYSE: NVS, Bristol-Myers Squibb (NYSE: BMY), Merck & Co., Inc. NYSE: MRK, Eli Lilly & Co. NYSE: LLY and Amgen Inc. NASDAQ: AMGN were trading normally following news that their drugs would be subject to next year's Medicare price negotiations.
2023-08-21 09:01:19 - Zacks Investment Research
New Strong Sell Stocks for August 21st
ALPMY, CYRX and DRCT have been added to the Zacks Rank #5 (Strong Sell) List on August 21, 2023.
2023-08-06 22:42:08 - Seeking Alpha
Astellas Pharma Inc. (ALPMF) Q2 2023 Earnings Call Transcript
Astellas Pharma Inc. (OTCPK:ALPMF) Q2 2023 Earnings Conference Call August 1, 2023 4:00 AM ET Company Participants Hiromitsu Ikeda - Corporate Head, Advocacy and Relations Naoki Okamura - Representative Director, President and CEO Yoshitsugu Shitaka - Chief Scientific Officer Tadaaki Taniguchi - Chief Medical Officer Claus Zieler - Chief Commercial Officer Conference Call Participants Hidemaru Yamaguchi - Citigroup Securities Kazuaki Hashiguchi - Daiwa Securities Naomi Kumagai - Mitsubishi UFJ Morgan Stanley Securities Akinori Ueda - Goldman Sachs Securities Shinichiro Muraoka - Morgan Stanley MUFJ Securities Madoka Sato - Schroder Investment Management Kasumi Haruta - Credit Suisse Securities Shinya Tsuzuki - Mizuho Securities Hiromitsu Ikeda Thank you very much for your participation on this earning call for Q1 FY 2023 Financial Results Ended June 30, 2023...